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Abstract
In this retrospective study, the efficacy and safety were examined for an intraperitoneal
chemotherapy protocol-cyclophosphamide, vincristine and prednisolone (IP-COP) in 26 cats with
malignant lymphoma. Certainly in cats fiercely resisting IV administration the IP route is a more
practical method, safer for the administrator and less stressful for the cat. Complete remission (CR)
rate was 76.9% (n= 20). Median duration of first remission was 421 days. Estimated 1- and 2-year
disease free period were 67.1 and 48.0%, respectively. Median duration of survival was 388 days and
estimated overall 1- and 2-year survival periods were 54.7 and 46.9% respectively. Young cats had a
more favourable prognosis. Reaching CR was essential for long-term survival. No specific IP-related
adverse events (AE) were seen. AE were generally scored as mild and were not excessively abundant.







Malignant lymphoma (ML) is one of the most
common malignancies seen in the cat in the
Utrecht University Clinic for Companion Ani-
mals (UUCCA).1 Reported estimate incidence rates
vary from 160 to 200 per 100 000 individuals.1,2
Incidence of ML and prevalence of the different
anatomical forms greatly vary in different popu-
lations, separated geographically or in time.3,4 In
The Netherlands, for instance, the most frequent
anatomic form is the mediastinal one.1,5,6 Causes
for these differences may be variation in feline
leukaemia virus (FeLV) status and breed differences
in the cat population.
In the 1960s, these tumourswere often associated
with retroviruses, predominantly FeLV infection.
The incidence of FeLV in The Netherlands is one of
the lowest in the world (<0.3%),1,4 due to decennia
long policy of testing and eliminating in the breed
cat population.1,2 The percentage of FeLV positive
ML in The Netherlands is also very low (<8%).1
Nevertheless, the incidence of feline ML remains
high.
The treatment of choice when assessing ML
is chemotherapy. Many variations in treatment
protocols exist. Protocols vary in efficiency
depending on the type of lymphoma and its
susceptibility to the agents. Combination protocols
tend to be more effective than single-agent ones
and long maintenance is required.3,7 At the
UUCCA, a multidrug protocol is used consisting of
cyclophosphamide, vincristine and prednisolone,
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Remission rates previously were found to differ per
anatomic location with an overall remission rate of
approximately 75%.1,8
Although the IV-based COP protocol is effective,
this route of administration in our experience
often was very hard to execute in frightened and
aggressive cats. This was mainly because the cats
resist tobeing restrained and injected intravenously.
Although sedation may then be considered, this
adds to theburdenof treatment andcosts, leadingus
to investigate intraperitoneal (IP) administration.
Arguments to consider this route as potentially
effective were found in literature demonstrating
high efficacy for other IP protocols in experimental
animals and the human.9,10 The goal was improving
safety for the administrator and reducing stress for
the animal. Because of its apparent success many
more cats have been treated with this IP-COP
protocol. The aim of this study was to investigate




All cats included in this study (n= 26) were
referred to the Utrecht University Clinic for
CompanionAnimals (UUCCA) andwere all treated
according to the COP protocol with solely IP
administration of the chemotherapeutics. Cats that
were partially treatedwith IP and IV injections were
excluded.
Diagnosis of ML was always confirmed prior
to treatment by either cytology or histology of a
biopsy of an organ or an excised lymph node.
Other serious medical illnesses were absent in these
animals.
Data collection
This study was conducted by assessing the clinic
database (Vetware®, in use since 2004) of the
UUCCA from 2004 to 2011. Information that
was obtained from this database included age,
breed, gender, the exact diagnose, medical history,
drug administration reports and reports of clinical
state and adverse events (AE; vomiting, diarrhoea,
anorexia, obstipation, fever, pain, hair loss or
dullness). In addition, possible pretreatment
with corticosteroids within 3 weeks prior to
chemotherapy was noted. As not all tumours in
these cats were staged, stage was not included as
part of the prognostic criteria study. FeLV/FIV
status was evaluated in 15 cats with an ELISA test.
Cats were classified according to six anatomi-
cal categories: nasal lymphoma, mediastinal lym-
phoma, alimentary lymphoma, lymphoma of the
liver, peripheral lymphomaandmiscellaneous types
of lymphoma.
Long term follow-up (i.e. after completion of
treatment) for cases where disease free period
(DFP) and survival time was no longer listed in the
database was conducted by phoning the owners.
Treatment
All cats that were eligible for this study were treated
according to a modified COP protocol (Table 1).
The original protocol was described byCotter et al.8
The modification lies in the fact that all injections
are given IP. Induction of remission was performed
with vincristine (0.75mg/m2; 0.1mg/mL; IP)
weekly inweeks 1, 2, 3 and4, and cyclophosphamide
(300mg/m2; 20mg/mL; IP) weekly in weeks 1 and
4, in separate administrations, combined with a
daily oral dose of prednisolone (50mg/m2). IP
Table 1. Chemotherapy protocol used in this study
Treatment week
Agent Dose Route 1 2 3 4 5 6 7 8 9 10 13 16 . . . a 52
Vincristine 0.75mg/m2 once IP X X X X X X X X
Cyclophosphamide 300mg/m2 once IP X X X X X X
Prednisolone 50mg/m2 daily PO X X X X X X X X X X X X X X
L-Asparginaseb 400 IU/kg once SC X
aPrednisolone is continued daily throughout the complete period, cyclophosphamide and vincristine once every three weeks.
bL-asparaginase was administered once only in 14 cats.
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injection was performed in a vertically fixated cat
1 cm lateral of the navel during a 30- to 40-second
period, using a butterfly needle which was gently
injected into the abdominal cavity. When no fluid,
either blood or urine, was noticed a Tevadaptor®
(TEVA Medical Ltd, Netanya, Israel) system was
connected for administration of hazardous drugs.
The butterfly needle was flushed with saline after
the chemotherapy administration before being
retracted. In 14 cats, a single administration of
L-asparaginase (400 IU/kg, SC) was given a few days
prior to this induction phase. After the first 4 weeks
of induction therapy, remission was maintained
with vincristine and cyclophosphamide injections
(IP) given on the same day with 3-week interval for
the duration of 1 year or until relapse of the illness.
Dosing is the same as in the induction phase.
Prednisolone is continued daily until relapse or for
1 year in remission. After this 1 year remission, the
dose is gradually decreased and stopped in a 3-week
period.
Evaluation of response
Response was only evaluated once all eligibility
criteria were satisfied. At each treatment the cats
were evaluated by the oncologists. Reports of the
findings were made in Vetware®. Response was
evaluated by clinical appearance and measurement
of tumour volume. In cats with an alimentary
or mediastinal tumour, abdominal ultrasounds
and thoracic radiographs were used, respectively,
to determine tumour volume and to evaluate
response. Innasal lymphomas, evaluationwas aided
by rhinoscopy. Other types of lymphomas were
evaluated through physical examination prior to
treatment.
Cats were considered to have no response or
progression when there occurred a less than 50%
decrease of total tumour volume of measurable
tumours or an increase in size/number of lesions,
respectively. Outcome was considered to be a
partial response (PR) when there was more than
50% decrease, but not complete disappearance of
tumour, no new lesions occurred and at least partial
improvement of clinical signs. Disappearance of
all measurable tumours and clinical signs was
considered as a complete response (CR). Response
rates are defined as the percentage of cats with CR
and PR. In order to be registered as responses, the
responses should sustain at least for 3 weeks.
Toxicity was looked upon by scoring of AE.
The AE scored were: vomiting, diarrhoea, fever,
anorexia, obstipation, hair loss, dullness and pain
(perception owner). Grading of these AE was done
according to VCOG-CTCAEv1.0.11
Survival time of all cats was calculated as the
interval from start of treatment till death of the
subject or time at which the cat was last known to
be alive. Only deaths due to ML or the treatment
were counted as an event. DFP of cats which went
into CR were calculated as the interval between
moment of confirmation of CR and relapse or the
date that the cat was last known to be free of disease,
only counting relapses as events.
Statistical analysis
Survival curves (DFP and survival time)were drawn
by the Kaplan–Meier method. Cats were censored
in the survival analysis because they were either (1)
lost to follow-up, (2) their death was not caused
by ML or the treatment or (3) they were alive at
the end of the study period. Censoring for DFP
was done in case of (1) lost to follow-up, (2)
death before occurrence of relapse or (3) relapse
did not occur before the end of the study period.
The variables age, sex, anatomic location, breed
and prednisolone pretreatment were evaluated for
predicting recurrence after CR and death using
the log-rank test and univariate and multivari-
ate Cox regression models. Differences among
groups were evaluated by the nonparametric tests
Mann–Whitney test and Kruskal–Wallis test
when Gaussian distribution could not be assumed.
Differences were considered to be significant at
P< 0.05. Statistical analysis of data was performed
with SPSS 16.0® computer software.
Results
Animal characteristics
A total of 26 cats conformed all selection criteria
and were included in this study. Of the 26 animals
in this study, 16 were seen in the last 2 years.
Half of the animals were male and 19 were of
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Table 2. Characteristics of the 26 cats included in the study
Variable Category n %
Gender Female intact 2 7.7
Female spayed 11 42.3
Male intact 0 0.0
Male castrated 13 50.0
Breed Domestic Shorthair 19 73.1
Bengal 1 3.8
Sphynx 1 3.8
Norwegian Forrest Cat 1 7.7
Russian blue 2 3.8
British shorthair 1 3.8
Siamese 1 3.8
Age <5 years 4 15.4
5–10 years 7 26.9
>10 years 15 57.7






the Domestic Shorthaired breed (Table 2). No
specific breed was significantly over-represented.
Mean age was 9.5 years (median 10.4 years and
range 2.1–14.3 years). No clear bimodal age
distribution but rather a normal distribution was
found. None of the 15 cats that were tested on
FeLV and FIV were found to be positive for either
one of the retroviruses. Ten cats had a medical
history of corticosteroid therapy within 3weeks
prior to chemotherapy induction, 15 did not and
for 1 cat there was no information available. In
the classification system used in this study the
nasal form was most common. Only one of the
cat was diagnosed with the mediastinal form,
a 2-year-old Siamese. Of the seven cats that
were categorized in the group ‘miscellaneous’,
three cats were diagnosed with a subcutaneous
lymphoma, two with a laryngeal lymphoma,
one with a tracheal and one with a retrobulbar
lymphoma.
Mean age of the group with nasal lymphoma was
10.6 years (SD 2.5 years), mean age of the cats with
peripheral lymphoma was 6.6 years (SD 2.6 years)
and mean age of the cats with alimentary lym-
phoma was highest with 12.6 years (SD 1.8 years).
All alimentary lymphomas were of the large
cell type.
Figure 1. Disease free period (DFP) curve of the 20 cats
that went into complete remission. Vertical bars represent
censored observations. Estimated 1-year and 2-year DFP
were 67.1 and 48.0%, respectively. Median DFP was
421 days.
Animal cooperation
All cats could be restrained by neck lifting – in
most with support of lower legs – during all
administrations and no injury occurred to animal
care takers or oncologists at any time. No canula
dislodgment during therapy was encountered. Cats
tolerated the procedure without any visible pain.
Response to treatment
Twenty animals (76.9%) of the total 26 cats went
into CR, 5 cats (19.2%) reached a PR and 1 cat
(3.8%) had no significant response. Median DFP
was 421 days, with a 1-year estimated DFP of 67.1%
and a 2-year estimated DFP of 48.0% (Fig. 1).
Animals with alimentary lymphoma had the lowest
DFP (228 days). The median DFP was highest for
cats with nasal and peripheral lymphoma, 388 and
421 days, respectively. The 1-year DFP rate for cats
with nasal lymphoma was 62.5%. No significant
differences in CR rates and DFP between neither
anatomic types nor breeds were found. Exact
time to reach remission could not be determined
because cats were only seen weekly, but was
less than 14 days for each of the individuals that
reached CR. Total median survival was 388 days
with a 1-year survival rate of 54.7% and a 2-year
survival rate of 46.9% (Fig. 2).
Of the 13 cats that had a relapse before the end of
this study, 6 animals underwent a second treatment;
3 cats were treated with L-asparginase only, 2 with
L-asparginase in combination with cytosar® and
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Figure 2. Survival curve for 26 cats with malignant
lymphoma treated with IP-COP. Vertical bars represent
censored observations. Estimated overall 1-year and 2-year
survival rate was 54.7 and 46.9%, respectively. Median
survival time was 388 days.
1 was treated with L-asparginase and leukeran.
None of these cats reached a second remission.
One cat that underwent relapse (421 days after
onset of treatment) underwent a second treatment
with the IP-COP protocol and did reach a new CR
with a new DFP of 1016 days while being treated
continuously.
Adverse events
In general, this chemotherapy protocol was well
tolerated by the cats. No therapy-related deaths
occurred. Seven AEs were scored according to
VCOG-CTCAEv1.0 terminology.11 Results are
listed in Table 3. The grading system consists of
five grades in which Grade 1 is mildest and Grade 5
is death. All AE except anorexia and hair loss were
graded as either Grade 1 or Grade 2, being mild
to moderate. No specific IP-administration related
AE occurred.
Diarrhoea was seen only as Grade 1 or 2, Grade
1 being defined as an ‘increase of >2 stools a day
over baseline’ and Grade 2 as an ‘increase of 2–6
stools a day’ or ‘need of parenteral fluids’.
Vomitingwhenpresentwas usually seen asGrade
1, less than three episodes of vomiting within 24
h. The cat that had one period of vomiting graded
as Grade 2 had less than three episodes a day for
2–5 days, after the first treatment. The cat had been
diagnosed with a gastrointestinal lymphoma.
Anorexia was usually seen as Grade 1 when
there is only a need of dietary change to maintain
appetite. In two cats, a Grade 2 anorexia was noted
because of a decreased oral intake for 2–3 days
without weight loss.
In one third of the cats one or more periods
of a Grade 1 obstipation was noted, occurring
only occasionally or intermitted and needing only
sparse use of laxatives. In three cats, the obstipation
became persistent and laxatives or enemas had to
be used constantly and therefore the AE was graded
as Grade 2.
Loss of hair or, more mildly, thinning of the coat
was either localized, Grade 1 (e.g. only the vibrissae)
or generalized (Grade 2 for thinning of the coat and
Grade 3 for denuding).
Pain was only reported once by an owner, to
whom the cat appeared to have a mild abdominal
pain for only 1 day. It is graded as 1 which is
defined as ‘mild pain, not interferingwith function’.
By following IP treatments no pain was recorded
anymore.
Several owners reported that cats were inactive
and made a fatigue impression after therapy. This
state was maintained for anywhere between 1
and 5 days. Grade 1 is defined as ‘mild lethargy
Table 3. Adverse events in 26 cats with malignant lymphoma after receiving intraperitoneal chemotherapy
Gradea
Adverse event Total number 1 2 3 4 5 Number of cats involved
Diarrhoea 7 2 5 0 0 0 3 (11.5%)
Vomiting 23 22 1 0 0 0 11 (42.3%)
Anorexia 20 17 3 0 0 0 9 (34.6%)
Obstipation 26 20 6 0 0 0 9 (34.6%)
Hair loss 8 4 3 1 0 0 7 (26.9%)
Pain 1 1 0 0 0 0 1 (3.8%)
Dullness/lethargy 20 20 0 0 0 0 10 (38.5%)
aGrading was performed according to VCOG-CTCAEv1.0 guidelines.
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over baseline’ and Grade 2 as ‘moderate lethargy
causing some difficulty with performing ADL’
(ADL= activities of daily living). Owner descrip-
tions made us decide to grade this inactive state as
Grade 1.
Prognostic factors for the duration of remission
and survival
Five pretreatment parameters were evaluated for
their prognostic predictive value for the duration
of survival and remission. Of these parameters only
age appeared to be prognostic for DFP length and
only when categorized in age-groups of 5 years
(i.e. 0–5 years, 5–10 years and 10–15 years). It
appeared that the youngest group had the longest
DFP (P= 0.046). Including other parameters in a
multivariate analysis did not lead to conversion, so
theywere excluded from the analysis. Survival times
alsowere significantly higher for the youngest group
of individuals (P= 0.031). No other prognostic
parameter was significant in predicting either DFP-
length or survival. Response to therapy (reaching
CR) was significant in predicting length of survival
but cannot be seen as a prognostic parameter
(P= 0.002).
Discussion
This study was commenced to prove safety and
efficacy of the IP-COP protocol used at our
department because of practical, safety and ethical
reasons. Administration is faster, venapuncture
is not needed and therefore there is no risk for
perivascular injection. Because of the shortness of
the procedure stress for the cat is minimal and
overly aggressive or frightened cats do not need to
be sedated or anaesthetized. Furthermore, the risk
for the administrator of getting bitten or scratched
is minimal even in aggressive animals when the
animal is fixed properly by the veterinary assistant.
In veterinary literature, we have not been able to
find any report describing the IP use of chemother-
apeutic agents in cats. In human medicine,
however, IP use of these agents is no exception. It
is used for treatment of patients with certain types
of tumour in the peritoneal cavity (e.g. ovarian
cancer or colon cancer).12 The fundamental goal of
this route of administration in humans is creating
a locally high dose of the chemotherapeutic drug
at the site of the tumour for a longer period of time
while reducing systemic toxicity. Indeed, the IP
administration of several chemotherapeutic drugs
has proven to be safer whilst still effective. Survival
rates of combined IV and IP therapy were higher
than IV therapy alone.12,13
When treating feline ML outside the peritoneal
cavity a locally high dose in this cavity is not the
primary goal. Since effects of chemotherapeutics are
dose- but mostly time-dependent, prolonged and
sufficient high systemic levels of chemotherapeutics
(and/or active metabolites) is what one should
aspire. In 2005, Miyagi et al. studied the 24-
h AUC (area under curve) for carboplatin after
IP and IV administration. These 24-h AUC were
exactly the same for both routes so they made
the very promising conclusion that the IP route
can be used for systemic therapy.14 Extrapolation
of results obtained in human studies is hard,
mainly because other drugs are used and often in
much higher concentrations. Lack of knowledge of
the pharmacokinetic values of chemotherapeutics
used in cats make predicting parameters like
bioavailability very difficult. For this further
pharmacodynamic studies have to be conducted.
In our study, thenasal formofMLwasmost often
diagnosed. In a previous study at our institute, the
mediastinal form was most common and nasal
lymphoma only accounted for 13%.1 So a certain
shift in anatomical location has taken place. This
increase in nasal lymphoma has been reported
elsewhere.3 There seems to be an overall increase in
patients with ML presented at our faculty. Most of
the cats in this study began treatment in 2009 and
2010. This increase in incidence was also reported
by elsewhere.2 Possibly more owners are willing to
treat their cats for ML.
The mean age of 9.5 years reported in our study
is consistent with ages reported elsewhere,15–17 but
higher than found in 2002 and earlier studies.8,18
The big difference in both age and anatomical
form can be explained by the large group of young
Siamese cats present in the earlier study. Siamese-
type cats are known to be genetically predisposed
for the development of mediastinal lymphoma.1,2
Several studies report a bimodal age distribution
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for cats with ML.1,2,16 The first peak (i.e. 1–2 years)
used to be explained by a FeLV infection leading
to ML in young animals, often in Siamese-type
breeds. This seems to be incorrect.1,17 Even when
there are hardly any FeLV positive cats a bimodal
distribution is seen.1,3 Other aetiologic factorsmust
play a role. In the study presented here, no clear
bimodal age distribution was apparent, rather a
normal distribution. Absence of a large group of
young Siamese – with only one in the current
study – may account for this. It is obvious that
FeLV plays a subordinate role in the population
treated in this study. This is in concurrence with
the earlier studies.1,4,15 In a recent study none
of the antigen-negative cats with lymphoma was
detectably infected with latent provirus FeLV,
thereby making a possible role of FeLV in our
study even further unlikely.19
The original COP protocol has already proven
to be effective.1,5,8,20 In this study, the median
overall survival time (388 days) was higher than
reported in an earlier study from our institute
(266 days)1 and also higher than reported with
other chemotherapy protocols, like the University
of Wisconsin-Madison and VCM protocols (both
210 days),16,18 and much higher than a single
doxorubicin protocol (84 days).21 The 1-year and 2-
year survival rates were 54.7 an 46.9%, respectively,
comparable to the 48.7 and 39.9%, respectively,
reached in our earlier study.1
Assessment of the remission rate in this study
shows a comparable result as previous COP
protocol studies.1,8 Reports of remission rates vary
between 29 and 79%.3 In this study, the CR rate
was 76.9%, comparable to the 75.4% in our earlier
study.1 This is higher than achieved by other
protocols, like Wisconsin-Madison protocols with
47%, VCM (vincristine, cyclophosphamide and
methotrexate) with 62% and single agent doxoru-
bicin with 26%, respectively.16,18,21 But also higher
than the one Moore et al. achieved using a COP
protocol,20 illustrating that outcome of treatment is
dependent on much more than solely the protocol
used; anatomical site, age of the cat, immunological
type and many more factors may play a role.
Duration of complete remission (i.e. DFP)
exceeds that of most other studies. Median DFP
was 421 days, compared to 251 days of the IV-COP
protocolofTeske et al. in2002, and264and281 days
of IV-COP protocols using other chemothera-
peutics in their maintanance.1,7,20 Single agent
protocols often have substantially lower DFP (e.g.
92 days).21 Median DFP was only exceeded by
Milner et al. who used a University of Wisconsin-
Madison protocol (654 days). In this study, how-
ever, 7 of the 38 cats had a small cell intestinal lym-
phoma, a formwhichhas amuchbetterprognosis.16
Estimated 1-year DFP was 67.1% and estimated
2-year DFP was 48.0%, depicting a fairly stable
remission after discontinuation of therapy at 1 year.
Yet again these figures are somewhat higher than
previous results (51.4 and 37.8%, respectively),1
other studies did not report these rates. Taken all
treatment results together, this study demonstrates
the IP-COP protocol to be at least as effective
as the IV-COP protocol and the other reported
protocols.
Peripheral lymphoma (421 days) and nasal
lymphoma (388 days) had longest median DFPs.
In previous studies cats with alimentary lymphoma
had poorest remission and survival time.1,7,8
Although not significant, this study seems to display
the same tendency. The mediastinal form most
often responds well to the COP protocol but less so
using other protocols.1,6,8 In conclusion; prognosis
for nasal and peripheral lymphoma is good and
prognosis for the alimentary form is poorer using
the COP protocol, either IV or IP.
The finding that young-aged cats are more likely
to have a longer DFP and longer survival periods is
noteworthy. This was the only significant prognos-
tic factor for a favourable outcome found in this
study even when other factors were included in a
multivariate model. Age as prognostic factor has
also been identified by Malik et al.4 Possible expla-
nations lie in difference in tumour type between
younger and older animals, although no significant
difference in mean age of the different types of MLs
were found in this study and also immunophe-
notype has not been proven prognostic in earlier
studies.22,23 Other aetiologic factors may play a
role in young animals to make chemotherapy more
effective. Pretreatment with corticosteroids did not
negatively influence outcome in the cats in this
study. This is in contrast to dogs where it is nega-
tively associated with treatment results.24 A certain
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predictive value cannot be excluded, however, since
there iswide variation in corticosteroid treatment in
the cats that underwent prior corticosteroid therapy
by private practitioners. Breed,1 anatomic site,7,8
FeLV status6,16 and stage of disease6,18 are variables
shown to have a prognostic value in other studies.
The fact that we could not identify these variables to
be prognostic in our study can be due to the limited
numbers of animals. Although not a real prognos-
tic factor in the narrow sense, the most important
indicator for reaching long remission and survival
times was achieving a CR (P= 0.01). Not reaching
CR should be regarded as treatment failure.1,6,8,16
We experienced that once relapse occurred
during first treatment a second treatment had
poor efficacy. Second treatment was conducted
with other chemotherapeutics (i.e. L-asparginase,
cytarabine, chlorambucil) than used in the COP-
protocol. Hence, tumours in these individuals
reached certain state of resistance in which none
of the chemotherapeutics we used were effective
anymore. Remarkably one cat that underwent
relapse 2months after the 1-year treatment protocol
reached a new CR in 2 days through resumption of
the IP-COP protocol and stayed in remission for
almost 3 years.
Foremost we want to report that no special AE
related to IP administration were reported nor seen
by the clinicians. The majority of all reported AE
was graded as mild (i.e. Grade 1). Obstipation
had the largest total number of episodes, but was
only reported in nine animals. Only a few of them
needed treatment with laxatives. Not a single cat
showed signs of haemorrhagic cystitis. Vomiting
was seen in 11 animals with a total of 23 episodes
where 22 were graded as Grade 1. A mild anorexic
state could almost always be counteracted by a
change of menu. Owners of ten cats reported a
certain dullness or lack of energy during a 2–3 day
period following drug administration. Loss of hair
was most often limited to loss of vibrissae. These
numbersmight seemhigh from a first point of view,
but are relatively low compared to the number of
drug administrations performed during the course
of this study. Furthermore, none of the owners
wished to stop therapy because of AE. So severity
can be considered low enough on behalf of the
animals (under given circumstances) and incidence
is low enough for owners to tolerate. It is hard to
compare these results with other studies because
none of them used this grading system. Other
studies reported a fair degree of gastrointestinal
toxicosis.16,20,21 Once again, from our point of view
one of themost important findings is the lack of any
specific IP-administration related AE. Besides the
clinical efficacy it is found that owners are generally
very satisfied with their choice of commencing
chemotherapy with the COP protocol.25,26
Limitations of this study include the small study
group, very low case numbers in certain groups
(e.g. mediastinal lymphoma or exotic breeds), lack
of a control group and the possible biases in case
selection. The low numbers result in lack of power
to reach significance and make it hard to execute a
reliable multivariate analysis. Another difficulty in
a retrospective study as presented is the difficulty
of interpreting and verification of the accuracy of
the case reports. Grading AE was hard because
we had to rely on owner reports. Furthermore, it
should be stated one more time that extrapolation
of obtained results to other populations is very
hard, mainly because of big differences in genetics
and retrovirus incidence.
Although this study might give the impression
that this technique of administration of vincristine
and cyclophosphamide is exquisitely easy and
‘ready-to-use’ for anyone no matter what expe-
rience they may have in chemotherapy handling,
a serious warning has to be given. The IP admin-
istration was performed by experienced oncolo-
gists in a situation where every safety aspect of
good veterinary practice (GVP) of preparation and
administration of cytostatic drugs was executed in
line of the ECVIM-CA guidelines in order to avoid
contamination of drugs.27
The main goal of this study was to investigate
the feasibility of IP administration, the efficacy and
lack of AE. Results seem to indicate that the IP-COP
protocol is indeed an effective one. Because of the
mild AE, AE quantitatively comparable to the IV
protocols and an absence of real IP-related AE we
feel safe to say that it can be seen as an equally
safe alternative for the IV administration. The next
step we will take in proving efficacy and safety of
this new route of administration is a controlled
pharmacokinetic experiment in which we assess
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serum levels of chemotherapeutics both after IV
and IP administration.
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